BRPI0620081B8 - composto e composição farmacêutica. - Google Patents

composto e composição farmacêutica.

Info

Publication number
BRPI0620081B8
BRPI0620081B8 BRPI0620081A BRPI0620081A BRPI0620081B8 BR PI0620081 B8 BRPI0620081 B8 BR PI0620081B8 BR PI0620081 A BRPI0620081 A BR PI0620081A BR PI0620081 A BRPI0620081 A BR PI0620081A BR PI0620081 B8 BRPI0620081 B8 BR PI0620081B8
Authority
BR
Brazil
Prior art keywords
compounds
disease
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0620081A
Other languages
English (en)
Inventor
Koike Hiroki
Hanazawa Takeshi
Original Assignee
Pfizer
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37912450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0620081(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Raqualia Pharma Inc filed Critical Pfizer
Priority to BR122020004679-1A priority Critical patent/BR122020004679B1/pt
Publication of BRPI0620081A2 publication Critical patent/BRPI0620081A2/pt
Publication of BRPI0620081B1 publication Critical patent/BRPI0620081B1/pt
Publication of BRPI0620081B8 publication Critical patent/BRPI0620081B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto derivado de benzimidazol e composição farmacêutica. esta invenção refere-se a compostos da fórmula (1): ou um sal farmaceuticamente aceitável deste, em que: a, b, x, r1, r2, r3, r4, r5, r 6, r7 e r8 são cada qual como descrito aqui ou um sal farmaceuticamente aceitável, e composições contendo tais compostos e o uso de tais compostos no tratamento de uma condição mediada por atividade antagonistica de bomba de ácido tal como, porém não limitado á, doença gastrointestinal, doença gastroesofágica, doença de refluxo gastroesofágico (gerd), úlcera péptica, úlcera gástrica, úlcera duodenal, úlceras induzidas por nsaid, gastrite, infecção por helicobacter pylori, dispepsia, dispepsia funcional, síndrome zollinger-ellison, doença do refluxo não erosivo (nerd), dor visceral, azia, náusea, esofagite, disfagia, hipersalivação, distúrbio das vias aéreas ou asma.
BRPI0620081A 2005-12-19 2006-12-06 composto e composição farmacêutica. BRPI0620081B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020004679-1A BR122020004679B1 (pt) 2005-12-19 2006-12-06 Composição farmacêutica

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75218105P 2005-12-19 2005-12-19
US60/752,181 2005-12-19
US80294406P 2006-05-23 2006-05-23
US60/802,944 2006-05-23
PCT/IB2006/003605 WO2007072146A1 (en) 2005-12-19 2006-12-06 Chromane substituted benzimidazoles and their use as acid pump inhibitors

Publications (3)

Publication Number Publication Date
BRPI0620081A2 BRPI0620081A2 (pt) 2011-11-01
BRPI0620081B1 BRPI0620081B1 (pt) 2020-10-20
BRPI0620081B8 true BRPI0620081B8 (pt) 2021-05-25

Family

ID=37912450

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0620081A BRPI0620081B8 (pt) 2005-12-19 2006-12-06 composto e composição farmacêutica.
BR122020004679-1A BR122020004679B1 (pt) 2005-12-19 2006-12-06 Composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020004679-1A BR122020004679B1 (pt) 2005-12-19 2006-12-06 Composição farmacêutica

Country Status (18)

Country Link
US (1) US7723321B2 (pt)
EP (1) EP1963311B1 (pt)
JP (1) JP4481344B2 (pt)
KR (1) KR101088247B1 (pt)
CN (2) CN102321077A (pt)
AR (1) AR058120A1 (pt)
AT (1) ATE471319T1 (pt)
BR (2) BRPI0620081B8 (pt)
CA (1) CA2631880C (pt)
DE (1) DE602006014996D1 (pt)
DO (1) DOP2006000285A (pt)
ES (1) ES2345726T3 (pt)
GT (1) GT200600514A (pt)
NL (1) NL2000371C2 (pt)
PE (1) PE20071182A1 (pt)
TW (1) TW200732326A (pt)
UY (1) UY30043A1 (pt)
WO (1) WO2007072146A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000413A1 (en) * 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
EP2452680B1 (en) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
KR101472686B1 (ko) 2013-07-09 2014-12-16 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 제조방법
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
KR102129842B1 (ko) * 2013-10-02 2020-07-06 주식회사 대웅제약 술포닐인돌 유도체 및 이의 제조방법
RU2693484C1 (ru) 2013-11-22 2019-07-03 СиЭль БАЙОСАЕНСИЗ ЭлЭлСи Антагонисты гастрина для лечения и профилактики остеопороза
CN105440016B (zh) * 2014-08-11 2018-08-31 江苏柯菲平医药股份有限公司 吲哚、氮杂吲哚类衍生物、其制备方法及其在医药上的应用
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
MA41730B1 (fr) * 2015-06-08 2019-03-29 Cj Healthcare Corp Utilisation de dérivé de benzimidazole pour l'acidité nocturne
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
KR101829685B1 (ko) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 안정성 및 용해도가 개선된 주사용 조성물
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
EP3559051B1 (en) * 2016-12-20 2021-03-24 ExxonMobil Chemical Patents Inc. Polymerization process
KR101960357B1 (ko) * 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
KR20190057569A (ko) 2017-11-20 2019-05-29 제일약품주식회사 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도
TWI676477B (zh) * 2017-12-05 2019-11-11 南韓商Ｃｊ醫藥健康股份有限公司 苯并咪唑衍生物用於夜間酸突破的用途
KR102789783B1 (ko) * 2018-08-28 2025-04-03 에이치케이이노엔 주식회사 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
MX2021002278A (es) * 2018-08-29 2021-08-11 Hk Inno N Corp Composición para erradicar helicobacter pylori.
CN109320485B (zh) * 2018-12-02 2021-06-18 江苏慧聚药业有限公司 合成特戈拉赞手性醇的方法
PL3927340T3 (pl) * 2019-02-18 2026-03-09 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca tegoprazan do zapobiegania nawrotowi choroby refluksowej przełyku
CN112851646B (zh) * 2019-11-12 2023-06-13 中国医学科学院药物研究所 特戈拉赞的制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN111303131B (zh) * 2020-03-19 2021-06-04 江苏慧聚药业有限公司 特戈拉赞(Tegoprazan)类似物及其合成方法
JP2023521197A (ja) * 2020-04-13 2023-05-23 エイチケー イノ．エヌ コーポレーション ベンズイミダゾール誘導体化合物を含む医薬組成物
CN114249694B (zh) * 2020-09-22 2025-06-17 浙江四维医药科技有限公司 一种特格拉赞中间体的制备方法
AR123872A1 (es) 2020-10-23 2023-01-18 Hk Inno N Corp Comprimido de desintegración oral, procedimiento de preparación del mismo, procedimiento para prevenir o tratar enfermedades y uso del mismo
CN112358450A (zh) * 2020-11-19 2021-02-12 南京艾康生物科技有限公司 一种4-(苄氧基)-2-甲基-1H-苯并[d]咪唑-6-羧酸的合成方法
KR20220141700A (ko) 2021-04-13 2022-10-20 에이치케이이노엔 주식회사 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
CN113527272B (zh) * 2021-08-06 2023-07-21 西安淳甄新材料有限公司 一种特戈拉赞的合成方法
WO2023106841A1 (ko) * 2021-12-08 2023-06-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
KR102708701B1 (ko) 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법
CN114805317A (zh) * 2022-05-20 2022-07-29 江苏威奇达药业有限公司 一种特戈拉赞的制备方法
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
KR20250054104A (ko) * 2022-08-30 2025-04-22 상하이 하오위안 케멕스프레스 컴퍼니, 리미티드 테고프라잔 결정형 b 및 이의 제조방법
WO2024087156A1 (zh) * 2022-10-28 2024-05-02 深圳市华先医药科技有限公司 4-羟基-n,n,2-三甲基苯并咪唑-6-甲酰胺的可放大生产方法
WO2024087155A1 (zh) * 2022-10-28 2024-05-02 深圳市华先医药科技有限公司 一种合成4-羟基-n,n,2-三甲基苯并咪唑-6-甲酰胺的方法
CN116253685B (zh) * 2022-12-30 2024-12-10 成都安满生物医药科技有限公司 一种特戈拉赞中间体的制备方法
KR102939994B1 (ko) 2023-01-05 2026-03-19 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240118377A (ko) 2023-01-27 2024-08-05 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
KR102638900B1 (ko) 2023-01-27 2024-02-21 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
KR102715562B1 (ko) 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법
CN118724858B (zh) * 2023-03-31 2025-09-19 上海医药工业研究院有限公司 一种(r)-苯并吡喃-4-醇类化合物的制备方法
WO2024210689A1 (ko) 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
CN116621821A (zh) * 2023-05-29 2023-08-22 宙晟智维生命科学(上海)有限公司 一种无定形的苯并咪唑基化合物及固体分散体
KR20240171624A (ko) 2023-05-31 2024-12-09 권대길 치환된 벤즈이미다졸의 결정형 및 이의 제조방법
CN116715660A (zh) * 2023-06-14 2023-09-08 上海柏狮生物科技有限公司 一种特格拉赞的无定型物及其制备方法
CN117024417A (zh) * 2023-06-27 2023-11-10 上海柏狮生物科技有限公司 一种特格拉赞的制备方法
CN116789654A (zh) * 2023-07-10 2023-09-22 杭州小蓓医药科技有限公司 一种特戈拉赞的制备方法
WO2025037242A1 (en) * 2023-08-14 2025-02-20 Ami Lifesciences Private Limited Solid forms of tegoprazan and process thereof
KR102689851B1 (ko) 2023-09-26 2024-07-30 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
CN122029159A (zh) * 2023-11-01 2026-05-12 拉夸里亚创药株式会社 苯并咪唑化合物的制备流程
KR20250066641A (ko) 2023-11-07 2025-05-14 엠에프씨 주식회사 테고프라잔 말리에이트염 1수화물 결정형 및 이의 제조방법
CN117903097B (zh) * 2024-01-04 2026-04-10 浙江永太科技股份有限公司 一种特戈拉赞关键中间体母液料的回收方法
KR20250118583A (ko) 2024-01-30 2025-08-06 진양제약주식회사 테고프라잔을 포함하는 제약 조성물
KR102825970B1 (ko) 2024-02-16 2025-06-26 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
KR20250178892A (ko) * 2024-06-20 2025-12-29 화일약품주식회사 테고프라잔의 신규 염 및 이의 제조방법
KR20260009778A (ko) 2024-07-10 2026-01-20 환인제약 주식회사 신규한 피롤로 피리딘 유도체 또는 이의 염 및 이를 포함하는 약학적 조성물
CN121622564A (zh) * 2024-09-04 2026-03-10 山东罗欣药业集团股份有限公司 一种焦谷氨酸替戈拉生注射液及其制备方法
WO2026063544A1 (ko) * 2024-09-20 2026-03-26 (주)에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법
WO2026067510A1 (zh) * 2024-09-29 2026-04-02 山东罗欣药业集团股份有限公司 一种替戈拉生注射剂及其制备方法
CN119409687A (zh) * 2024-10-31 2025-02-11 西安丽彩医药研发有限公司 一种钾离子竞争性酸阻滞剂的非晶态固体形式及其制备方法
KR20260082181A (ko) 2024-11-27 2026-06-04 (주) 팜젠사이언스 신규한 피롤 유도체 화합물 및 이를 포함하는 위산분비 억제용 약제학적 조성물
CN121293190A (zh) * 2025-01-23 2026-01-09 都创(上海)医药科技股份有限公司 替戈拉生化合物的晶型及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
US5444775A (en) 1993-11-09 1995-08-22 Tobish; John J. Telephone key selection aid
SE9602286D0 (sv) * 1996-06-10 1996-06-10 Astra Ab New compounds
GB9914022D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
AR043063A1 (es) 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
AR049168A1 (es) * 2004-05-18 2006-07-05 Altana Pharma Ag Derivados de benzimidazol
JP2008543824A (ja) * 2005-06-14 2008-12-04 ファイザー株式会社 アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
KR20080080195A (ko) 2008-09-02
CN101341149A (zh) 2009-01-07
WO2007072146A1 (en) 2007-06-28
GT200600514A (es) 2007-07-17
NL2000371A1 (nl) 2007-06-20
CN102321077A (zh) 2012-01-18
HK1125368A1 (en) 2009-08-07
CA2631880C (en) 2011-03-29
PE20071182A1 (es) 2008-02-07
ATE471319T1 (de) 2010-07-15
TW200732326A (en) 2007-09-01
BRPI0620081B1 (pt) 2020-10-20
BRPI0620081A2 (pt) 2011-11-01
CA2631880A1 (en) 2007-06-28
ES2345726T3 (es) 2010-09-30
CN101341149B (zh) 2011-06-08
BR122020004679B1 (pt) 2021-09-21
EP1963311B1 (en) 2010-06-16
US20070142448A1 (en) 2007-06-21
UY30043A1 (es) 2007-07-31
DE602006014996D1 (de) 2010-07-29
NL2000371C2 (nl) 2007-09-06
JP2009520017A (ja) 2009-05-21
EP1963311A1 (en) 2008-09-03
AR058120A1 (es) 2008-01-23
US7723321B2 (en) 2010-05-25
JP4481344B2 (ja) 2010-06-16
KR101088247B1 (ko) 2011-11-30
DOP2006000285A (es) 2007-07-31

Similar Documents

Publication Publication Date Title
TW200732326A (en) Chromane substituted benzimidazole derivatives
ATE512969T1 (de) Benzimidazolderivate als selektive säurepumpenhemmer
CL2008002834A1 (es) Compuestos heterociclicos de 5 miembros, composicion farmaceutica, util para el tratamiento de la ulcera peptidica, sindrome de zollinger-ellison, gastritis, esofagitis por reflujo, enfermedad sintomatica por reflujo gastroesofagico, esofago de barrett, cancer gastrico, hiperacidez gastrica o ulcera debido a estres posquirurgico.
EE04279B1 (et) Omeprasooli kristalne vorm
JP2009520017A5 (pt)
NZ591793A (en) Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
PE20091307A1 (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica
ATE442140T1 (de) Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
PE20090109A1 (es) Compuestos pirrolicos como inhidores de la bomba de protones
PE20091680A1 (es) Cristal de compuestos de bencimidazol
SE9702483D0 (sv) New compound
ATE504570T1 (de) Tartratsalz aus isofagomin und verwendungsverfahren dafür
NO20092464L (no) Faste former av rasemisk ilaprazol
BR0211101B1 (pt) Processo melhorado para preparação de compostos tipo benzimidazol
NO20072764L (no) Kromanderivater som er nyttige syrepumpeantagonister
UY30205A1 (es) Derivados de cromano, sales del mismo farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
WO2007072142A3 (en) Benzimidazole-5-carboxamide derivatives
SE0302382D0 (sv) New salts II
WO2007026218A3 (en) Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
JP2008524199A5 (pt)
RU2015106931A (ru) Лекарственное средство от гастроэзофагеальной рефлюксной болезни
TH90875A (th) อนุพันธ์เบนซิมิดาโซลที่ถูกแทนที่ด้วยโครเมน
YU32301A (sh) Novi kristalni oblik omeprazola

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RAQUALIA PHARMA INC. (JP)

Free format text: TRANSFERIDO DE: PFIZER INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF